Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial

Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.